Skip to main content
Clinical Trials/NL-OMON44812
NL-OMON44812
Completed
Phase 3

Enhancement of exposure therapy for social anxiety disorder with testosterone: A randomized placebo controlled clinical trial - Testosterone enhancement of exposure therapy in SAD

ProPersona (Nijmegen)0 sites54 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
performance anxiety
Sponsor
ProPersona (Nijmegen)
Enrollment
54
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
August 20, 2019
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
ProPersona (Nijmegen)

Eligibility Criteria

Inclusion Criteria

  • \- Woman, 18\-45 years old
  • \- Social Anxiety Disorder (SAD) as established with a structured interview (MINI), and with speech anxiety as primary fear
  • \- Self reported SAD symptoms above clinical cut\-off (score \> 30 on the Liebowitz Social Anxiety Scale)

Exclusion Criteria

  • \- Prior non response to exposure therapy (i.c. speech exposure) for SAD symptoms, as defined by the patient\*s report of receiving specific and regular exposure assignments as part of previous therapy.
  • \- Entry of patients with other mood or anxiety disorders will be permitted in order to
  • increase accrual of a clinically relevant sample; however in cases where SAD is not judged
  • to be the predominant disorder, participants will not be eligible.
  • \- Psychosis or delusion disorders (current or in the past)
  • \- Patients with significant suicidal ideations or who have enacted suicidal behaviors within 6
  • months prior to intake will be excluded from participation and referred for appropriate clinical
  • intervention.
  • \- Mental retardation
  • \- Substance abuse or alcohol dependence

Outcomes

Primary Outcomes

Not specified

Similar Trials